Our Purpose Is to Make a Difference for Patients
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting immunotherapies for the treatment of cancer. Immatics is sponsoring several clinical trials to deliver the power of T cells to patients with cancer. The purpose of these trials is to develop innovative immunotherapies aimed at targeting a patient’s tumor selectively and effectively.
Clinical Trials
The following clinical trials are currently open and actively recruiting participants.
Contact us to learn more about the process and how you or someone you know might be able to take part.
SUPRAME (NCT06743126) is a Phase 3, multicenter, open-label, randomized, actively controlled, parallel-group clinical trial to evaluate the efficacy, safety and tolerability of treatment with anzu-cel (anzutresgene autoleucel, IMA203) administered at the recommended Phase 2 dose versus investigator’s choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma.
The IMA401-101 Phase 1 trial (NCT05359445) is evaluating the safety, tolerability and initial anti-tumor activity of TCER® IMA401 in patients with recurrent and/or refractory solid tumors. TCER® IMA401 is a TCR Bispecific molecule that targets MAGEA4/8.
For more information on this clinical trial, click here
The IMA402-101 Phase 1 trial (NCT05958121) is evaluating safety, tolerability and anti-tumor activity of TCER® IMA402 in patients with recurrent and/or refractory solid tumors. TCER® IMA402 is a TCR Bispecific molecule that targets PRAME (preferentially expressed antigen in melanoma).
For more information on this clinical trial, click here
Our Two Therapeutic Modalities
You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information
You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationConnect with Clinical Trial Opportunities
If you or someone you care for may be interested in an Immatics clinical trial, talk to your healthcare provider to explore potential eligibility.
For healthcare professionals, contact us to learn more about current trials and how to refer a patient.
